RE: The “LTHs” trading19 Nov 2025 23:00
£5.6m required for January 2026. Guess I was right and JustHereForFleecing and his crew misleading yet again.
Still going to follow him? 🤯
The Group will have insufficient working capital after Admission, and further funds will be required to
be invested in the first quarter of 2026 for the Group to continue its activities and thereafter to complete
Phase I trials of HG-CT-1 in both adult and pediatric patients.
The Company is of the opinion that the working capital available to the Group will be insufficient for its present
requirements, that is, for at least the next 12 months from the date of this document. Following Admission, the
Directors expect that the Group will have an aggregate funding shortfall of approximately £15.6 million to
enable it to complete the Phase I clinical trials of HG-CT-1 in both adult and pediatric patients over the period
to December 2028.
To address this anticipated funding shortfall, the Group will require additional working capital of approximately
£5.6 million by the end of January 2026 in order to continue its product development activities, with a primary
focus on HG-CT-1, to the end of 2026 and an additional £10 million during the period from 2027 to 2028. This
amount is expected to cover the ongoing development of the Group’s other product candidates within its
product portfolio, as well as general corporate overheads and operating expenses for the period from February
2026 to December 2028.
There can be no assurance that either the funding shortfall anticipated in February 2026 or the subsequent
financing requirements necessary to meet the Company’s objectives over the three-year period from 2026 to
2028 will be met in whole or in part. Furthermore, there can be no assurance that the Group will be able to
obtain such financing on terms acceptable to it, or at all.
In circumstances where insufficient funding were to be forthcoming to enable the Company to implement its
business plan through 2026, the Directors would use all endeavours to sell an interest in the development of
HG-CT-1, as well as its other product candidates. The Directors are reasonably confident that they would be
able to do so based on the data received to date in the Phase 1 trial of HG-CT-1 and discussions with a large
pharmaceutical company. If, ultimately, the Directors were unable to do so and had exhausted all other actions
to fund the Company’s product development through Phase 1 in respect of HG-CT-1, the Company would
need to wind down its operations, realise its assets and may enter administration or liquidation in the period
February to April 2026, if and to the extent there are creditors of the Company who cannot be paid. In such an
event, the Company would no longer manage the affairs of the Company or the realisation of its assets. Such
an outcome would be expected to result in the cancellation of the Ordinary Shares from admission to the
Official List and in shareholders rec
Sign In
Follow the stocks
